ALNY
HealthcareAlnylam Pharmaceuticals, Inc.
$397.83
$-2.34 (-0.58%)
Jan 5, 2026
Price History (1Y)
Analysis
Alnylam Pharmaceuticals, Inc. is a biotechnology company operating within the healthcare sector. It has a significant market presence with a market capitalization of $52.56B and a large workforce of 2230 employees. The company's financial health indicates strong profitability, with gross margin at 83.9%, operating margin at 29.5%, and profit margin at 1.4%. Returns on equity and assets are also substantial, at 32.7% and 3.7%, respectively. The balance sheet reveals a significant debt of $2.77B against cash reserves of $2.72B, resulting in a debt-to-equity ratio of 1185.71. Valuation metrics show a high P/E ratio of 1420.82, but also a forward P/E of 35.58 and a price to sales ratio of 16.37. Revenue growth has been substantial at 149.3% year-over-year, while earnings growth is not available. The company does not currently pay dividends, with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $52.56B
- P/E Ratio
- 1420.82
- 52-Week High
- $495.55
- 52-Week Low
- $205.87
- Avg Volume
- 1.26M
- Beta
- 0.32
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 2,230